Biodesy Closes on $15M Series A Round, Appoints Greg Yap as CEO | GenomeWeb

NEW YORK (GenomeWeb News) – Biotech firm Biodesy said today that it has closed a $15 million Series A financing round with investments from 5AM Ventures, Pfizer Venture Investments, and Roche Venture Fund.

Additionally, the company announced that it has named Greg Yap as CEO and a director. Biodesy founder Joshua Salafsky has been appointed as chief science officer and a director.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: system to track intron gains and losses, role of RUNX during mitosis, and more.

French officials release a report and move to strength safety measures for clinical trials, ScienceInsider reports.

Researchers find different molecular signatures in cancers from men as compared to those from women, the Wall Street Journal reports.

Researchers trace the deaths of a pair of newborn siblings to a mutation in their LIPT1 genes through whole-exome sequencing, Stat News reports.